Ongoing 13 Feb 2024

FURMO-002

A phase 1b dose escalation and dose expansion study evaluating the safety, pharmacokinetics, and antitumour activity of Furmonertinib in patients with advanced or metastatic non-small cell lung cancer with activating EGFRor her2 mutations.

Enquire

Trial overview

Clinical Area

Medical Oncology

Disease / Condition

Lung cancer

Study Phase

Trial registration

Number: NCT05364073

https://clinicaltrials.gov/study/NCT05364073

GenesisCare Location(s)

GenesisCare North Shore

Principal Investigator(s)

Dr Nick Pavlakis

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.

First name *

Last name *

Email *

Phone *

State *

Postcode *

What is the reason for enquiry?

How would you prefer to be contacted? *

Phone

By submitting you acknowledge we will use the information you are providing to contact you about your enquiry. For more information about how we handle your personal information, please refer to the GenesisCare Privacy Policy.

FURMO-002

Trial overview

Thank you for submitting.

An unexpected error has occurred.

How can we help?

GenesisCare

Website policies

Contact us

Media & Social